These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 30044269

  • 1. BILATERAL CHOROIDAL DETACHMENTS SECONDARY TO IPILIMUMAB AND PEMBROLIZUMAB USE.
    O'Bryhim BE, Sychev Y, Rao PK.
    Retin Cases Brief Rep; 2021 May 01; 15(3):230-233. PubMed ID: 30044269
    [Abstract] [Full Text] [Related]

  • 2. Pembrolizumab-related Bilateral Ocular Hypotony, Uveitis, Cataracts, Exudative Retinal, and Choroidal Detachments: An Unusual Success Story.
    Golash V, Almeida G.
    J Immunother; 2020 May 01; 43(9):283-285. PubMed ID: 32740318
    [Abstract] [Full Text] [Related]

  • 3. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.
    Lancet; 2017 Oct 21; 390(10105):1853-1862. PubMed ID: 28822576
    [Abstract] [Full Text] [Related]

  • 4. Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab.
    Navarro-Perea C, Garcia-Gonzalez J, Perez-Blazquez E.
    Indian J Ophthalmol; 2019 Dec 21; 67(12):2075-2077. PubMed ID: 31755465
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ, Shirai K.
    J Immunother; 2019 May 21; 42(4):136-141. PubMed ID: 30933044
    [Abstract] [Full Text] [Related]

  • 7. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.
    Eur J Cancer; 2017 Nov 21; 86():37-45. PubMed ID: 28961465
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF, Lipson E, Suresh K, Cappelli LC, Monaco SE, Maleki Z.
    Hum Pathol; 2019 Sep 21; 91():69-76. PubMed ID: 31279873
    [Abstract] [Full Text] [Related]

  • 10. Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.
    Reid G, Lorigan P, Heimann H, Hovan M.
    Ocul Immunol Inflamm; 2019 Sep 21; 27(6):1012-1015. PubMed ID: 29672247
    [Abstract] [Full Text] [Related]

  • 11. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM, Robert C, Richtig E, Miller WH, Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J.
    Eur J Cancer; 2017 Nov 21; 86():115-124. PubMed ID: 28987768
    [Abstract] [Full Text] [Related]

  • 12. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
    Donaldson M, Owen JL, Choi JN.
    JAMA Dermatol; 2018 Jul 01; 154(7):846-847. PubMed ID: 29800007
    [No Abstract] [Full Text] [Related]

  • 13. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 01; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 14. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
    Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.
    Lancet Oncol; 2015 Aug 01; 16(8):908-18. PubMed ID: 26115796
    [Abstract] [Full Text] [Related]

  • 15. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F.
    J Oncol Pharm Pract; 2017 Dec 01; 23(8):620-624. PubMed ID: 27590328
    [Abstract] [Full Text] [Related]

  • 16. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J.
    BMJ; 2018 Nov 08; 363():k4226. PubMed ID: 30409774
    [Abstract] [Full Text] [Related]

  • 17. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment.
    Tsui E, Madu A, Belinsky I, Yannuzzi LA, Freund KB, Modi YS.
    JAMA Ophthalmol; 2017 Dec 01; 135(12):1455-1457. PubMed ID: 29145556
    [No Abstract] [Full Text] [Related]

  • 18. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K, Nakamura Y, Fujisawa Y, Endo R, Tanaka R, Ishitsuka Y, Maruyama H, Watanabe R, Okiyama N, Fujimoto M.
    Eur J Dermatol; 2018 Feb 01; 28(1):129-130. PubMed ID: 29400284
    [No Abstract] [Full Text] [Related]

  • 19. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ, Carlos G, Wakade D, Sharma R, Fernandez-Penas P.
    Melanoma Res; 2016 Aug 01; 26(4):417-20. PubMed ID: 27031538
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kieker F, Dippel E, Rösch A, Simon JC, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D, Dermatologic Cooperative Oncology Group.
    Lancet; 2020 May 16; 395(10236):1558-1568. PubMed ID: 32416781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.